Clinical trials: Hypertrophy, Left Ventricular
Essential Hypertension, Left Ventricular Hypertrophy
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CandLE (NCT00607633)
- Volunteers
- 686 people
- Sponsor
- AstraZeneca
Left Ventricular Hypertrophy
Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study
This is a prospective, open label, single-center study, in kidney transplant recipients with stable renal function for 12 and 120 months after transplantation, that are in use use of calcineurin inhibitors, azathioprine, and…
- Trial name
- NCT02493465
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto de Urologia e Nefrologia
Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
The purpose of this study is to assess the effectiveness of squat-to-stand maneuver in eliciting left ventricular outflow gradients in patients with Hypertrophic Cardiomyopathy (HCM) compared to Valsalva, amyl nitrite inhalation…
- Conditions
- Hypertrophic Cardiomyopathy, Hypertrophic Obstructive Cardiomyopathy, Cardiomyopathy, Hypertrophic
- Trial name
- NCT04905173
- Testing
- Squat-to-stand maneuver, Amyl nitrite inhalation, Valsalva
- Sponsor
- Mayo Clinic
Aortic Valve Stenosis, Ventricular Hypertrophy
Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis
The purpose of the study is to see if statin therapy will optimize myocardial response to cardiopulmonary bypass during aortic valve replacement (AVR) for aortic valve stenosis (AVS) (Phase I) and optimize left ventricular…
- Trial name
- NCT00811330
- Testing
- Atorvastatin 80 mg
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
Hypertension, Left Ventricular Hypertrophy
Hypertension in Hemodialysis
How high blood pressure in hemodialysis patients should be diagnosed and treated using medications or without medications is the purpose of this study.
- Trial name
- NCT00067665
- Testing
- Ultrafiltration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Left Ventricular Hypertrophy
Demographical and Clinical Profile of Patients With Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) is the most common result of the heart trying to pump blood against the high afterload, as in hypertension and aortic stenosis.Although hypertension is the most common cause of LVH, LVH can also…
- Trial name
- NCT04275882
- Testing
- Electrocardiogram
- Where
- Turkey (Türkiye)
- Volunteers
- 886 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Hypertension, Left Ventricular Hypertrophy
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.
- Trial name
- NCT01425411
- Testing
- valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Mustafa Kemal University
Type 2 Diabetes, Left Ventricular Hypertrophy
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
Left ventricular hypertrophy (LVH) is common in people with type 2 diabetes (70%) and is the strongest independent risk factor for cardiovascular events and all-cause mortality that there is.
- Trial name
- DAPA-LVH (NCT02956811)
- Testing
- Dapagliflozin
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- University of Dundee
Cardiomyopathy, Hypertrophic
Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Wall Thickness> 15mm
The investigators sought to evaluate the morphological and functional changes and prognosis of participants with unexplainable precordial deep T-wave inversion on ECG and with apical thickness less than 15mm.
- Trial name
- NCT02692508
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)
This study will examine the effectiveness of the drug cyclosporine in treating hypertrophic cardiomyopathy (HCM), a condition in which the heart muscle thickens.
- Trial name
- NCT00001965
- Testing
- Cyclosporine A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Arterial Stiffness, CHRONIC RENAL FAILURE
Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.
The aims of the presented study are as follows: 1. To evaluate the endothelial function and arterial stiffness in a large cohort of prevalent CKD patients by means of non-invasive applantion tonometry. 2.
- Conditions
- Arterial Stiffness, CHRONIC RENAL FAILURE, Left Ventricular Hypertrophy
- Trial name
- NCT01579032
- Where
- 2 sites in Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hypertension Complicated, Hypertrophy, Left Ventricular
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated…
- Conditions
- Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
- Trial name
- BVreduce (NCT03180593)
- Testing
- Valsartan 80 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Trinity Hypertension & Metabolic Research Institute
Heart Failure, Cardiomyopathies
Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Premature cardiovascular disease (CVD) is the leading cause of death in patients with kidney disease (CKD). Excessive cardiac mortality is thought to be secondary to non-atherosclerotic processes, with left ventricular (LV)…
- Conditions
- Heart Failure, Cardiomyopathies, Chronic Kidney Diseases, Hypertrophy, Left Ventricular
- Trial name
- TRUE-TypeCKD (NCT03749551)
- Testing
- cardiac magnetic resonance (CMR) post haemodialysis
- Where
- Germany
- Volunteers
- 276 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Heart Failure, Coronary Disease
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) is a large, prospective, hospital-based cohort study to investigate the following: Characteristics of patients with chronic heart failure and…
- Conditions
- Heart Failure, Coronary Disease, Heart Valve Diseases, Cardiomyopathies
- Trial name
- NCT00418041
- Where
- Japan
- Volunteers
- 10,000 people
- Sponsor
- Hiroaki Shimokawa, MD, PhD
Left Ventricular Hypertrophy
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Hypothesis/Study question In infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure/performance and lung water content? Study objectives To measure effects…
- Trial name
- SPEC (NCT04644094)
- Testing
- Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Cardiovascular Diseases, Carotid Intimal Media Thickness
Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Cardiovascular disease (CVD) is the major risk factor for death in end stage renal diseases (ESRD). Approximately 80% of ESRD patients have some degrees of left ventricular abnormalities at initiation of dialysis.
- Conditions
- Cardiovascular Diseases, Carotid Intimal Media Thickness, Left Ventricular Hypertrophy, Mean Platelet Volume
- Trial name
- NCT03759002
- Testing
- Imaging, Blood sampling
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Left Ventricular Hypertrophy
Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients
This prospective, randomized, controlled study aims to evaluate the usefulness of the new body composition monitor (BCM) device as a method to improve volume control in hemodialysis (HD) patients and compare the results with…
- Trial name
- NCT00974857
- Testing
- BCM, control group
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Ege University
Atherosclerosis, Heart Diseases
Cardiac MR of Subclinical CVD: Impact of Age
To use magnetic resonance imaging to identify subclinical atherosclerosis and left ventricular hypertrophy in the Framingham Heart Study cohort.
- Conditions
- Atherosclerosis, Heart Diseases, Cardiovascular Diseases, Hypertrophy, Left Ventricular
- Trial name
- NCT00041418
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Anemia of Chronic Kidney Disease, Endothelial Dysfunction
Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient
The fibroblast growth factor-23-bone-kidney axis is part of newly discovered biological systems linking bone to other organ functions through a complex endocrine network that is integrated with the parathormone/vitamin D axis and…
- Conditions
- Anemia of Chronic Kidney Disease, Endothelial Dysfunction, Left Ventricular Hypertrophy, Fibroblast Growth Factor 23
- Trial name
- NCT03193073
- Testing
- detailed echocardiography, serum fibroblast growth factor-23, flow mediated dilatation of forearm
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Omnia Mohammed Hashem